Prediction of ROR1 and CAV1 expression from whole-exome sequencing of tumor tissue and plasma cfDNA to infer the efficacy of B013 plus nab-paclitaxel in triple-negative breast cancer

Accurate prediction of response to targeted anticancer therapy frequently depends on the expression level of the drug target. However, transcriptomic profiling requires tumor tissue that is often unavailable, and circulating cell-free DNA (cfDNA) sequencing carries no expression information. Here, in an in silico companion study to a trial of ROR1 antibody plus nab-paclitaxel in triple-negative breast cancer (TNBC), we transformed whole-exome sequencing (WES) data into somatic activity profiles of signaling pathways (sAPSPs) using the previously published DAGM framework, and used them together

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.